US FDA lifts import alert imposed on Sun Pharma's Mohali facility

The US Food & Drug Administration (FDA) will lift the import alert imposed on Sun Pharma’s Mohali (Punjab) manufacturing facility and remove the facility from the Official Action Initiated (OAI) status. This proposed action will clear the path for Sun Pharma to supply approved products from the Mohali facility to the US market, subject to normal US FDA regulatory requirements.